KR880007079A - 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법 - Google Patents

레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법 Download PDF

Info

Publication number
KR880007079A
KR880007079A KR870014383A KR870014383A KR880007079A KR 880007079 A KR880007079 A KR 880007079A KR 870014383 A KR870014383 A KR 870014383A KR 870014383 A KR870014383 A KR 870014383A KR 880007079 A KR880007079 A KR 880007079A
Authority
KR
South Korea
Prior art keywords
retrovirus
pharmaceutical composition
ene
therapeutic agent
dioxythymidine
Prior art date
Application number
KR870014383A
Other languages
English (en)
Other versions
KR960000433B1 (ko
Inventor
린 타이-순
에이취 프루소프 윌리암
Original Assignee
도로시 케이 로빈슨
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25478432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880007079(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 도로시 케이 로빈슨, 예일 유니버시티 filed Critical 도로시 케이 로빈슨
Publication of KR880007079A publication Critical patent/KR880007079A/ko
Application granted granted Critical
Publication of KR960000433B1 publication Critical patent/KR960000433B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음.

Description

레트로비루스에 감염된 환자치료에 있어서의 3′-디옥시티미딘-2′-엔(3′-디옥시-2′,3′-디디하이드로티미딘)의 사용법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 단독의 또는 희석제와 혼합된, 또는 의약의 형태의 3′-디옥시티미딘-2′-엔으로 되어 있는 것을 특징으로 하는 레트로비루스로 감염된 온혈동물의 치료제.
  2. 제1항에 있어서, 레트로비루스가 물로니 쥐 백혈병 비루스인 것을 특징으로 하는 치료제.
  3. 제1항에 있어서, 레트로비루스가 HTLV III/LAV인 것을 특징으로 하는 치료제.
  4. 제1항에 있어서, 정맥내 투여시는 일당 체중 kg당 0.01 내지 10mg양의 3′-디옥시티미딘-2′-엔이 사용되는 것을 특징으로 하는 치료제.
  5. 고체, 액체 또는 액화기체 희석제와 혼합된 항레트로비루스 유효량의 3′-디옥시티미딘-2′-엔을 활성성분으로 포함하는 것을 특징으로 하느 약학조성물.
  6. 제5항에 있어서, 상기 활성성분 0.5 내지 90%를 포함하는 것을 특징으로 하는 약학조성물.
  7. 제5항에 있어서, 스테릴 생리학적 등침투성 수용액의 형태로 구성되는 것을 특징으로 하는 약학조성물.
  8. 제5항에 있어서, 상기 활성성분 0.5 내지 90%를 포함하는 것을 특징으로 하는 약학조성물.
  9. 항 레트로비루스 유효량의 3′-디옥시티미딘-2′-엔 및 불활성 약학용 딤체로 구성되는 것을 특징으로 하는 사용단위형의 의약.
  10. 제9항에 있어서, 의약이 정제, 환약, 당의정, 캡슐, 캡레트, 앰플 또는 좌약의 형으로 구성되는 것을 특징으로 하는 의약.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870014383A 1986-12-17 1987-12-17 레트로비루스에 감염된 환자치료에 사용되는 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 항바이러스 조성물 KR960000433B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/942,666 US4978655A (en) 1986-12-17 1986-12-17 Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
US942,666 1986-12-17
US942666 1986-12-17

Publications (2)

Publication Number Publication Date
KR880007079A true KR880007079A (ko) 1988-08-26
KR960000433B1 KR960000433B1 (ko) 1996-01-06

Family

ID=25478432

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870014383A KR960000433B1 (ko) 1986-12-17 1987-12-17 레트로비루스에 감염된 환자치료에 사용되는 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 항바이러스 조성물

Country Status (22)

Country Link
US (1) US4978655A (ko)
EP (1) EP0273277B1 (ko)
JP (1) JPH07116041B2 (ko)
KR (1) KR960000433B1 (ko)
AT (1) ATE77554T1 (ko)
AU (1) AU593405B2 (ko)
CA (1) CA1293447C (ko)
DE (1) DE3780016T2 (ko)
DK (1) DK174627B1 (ko)
EG (1) EG19157A (ko)
ES (1) ES2038650T3 (ko)
FI (1) FI875544A (ko)
GR (1) GR3005691T3 (ko)
HK (1) HK55896A (ko)
IE (1) IE60866B1 (ko)
IL (1) IL84790A (ko)
LU (1) LU88822I2 (ko)
NL (1) NL960024I2 (ko)
NZ (1) NZ222935A (ko)
PH (1) PH26380A (ko)
PT (1) PT86346B (ko)
ZA (1) ZA877171B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
US6207650B1 (en) 1989-05-15 2001-03-27 Bristol-Myers Squibb Company Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
US5608048A (en) * 1995-06-05 1997-03-04 Bristol-Myers Squibb Company d4 T polymorphic Form 1 process
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
CA2189097A1 (en) 1995-11-15 1997-05-16 Pin-Fang Lin Composition and method of treating retroviral infection
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
WO2000016625A1 (en) * 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Antiviral drug compositions containing lithium inorganic salts
KR20030011805A (ko) 2000-03-30 2003-02-11 브리스톨-마이어스스퀴브컴파니 스타부딘을 함유하는 서방성 비들렛
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
CA2514466C (en) * 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
US20040200730A1 (en) * 2003-04-14 2004-10-14 Kyo Jibiki Hydrometallurgical copper recovery process
EP2258376B1 (en) 2004-07-27 2019-02-27 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
BRPI0617074A2 (pt) * 2005-08-31 2011-07-12 Cipla Ltd composição farmacêutica, uso de lamivudina, nevirapina e stavudina, uso de stavudina, lamivudina e nevirapina, método para tratar uma infecção viral em um humano, método para preparar uma composição farmacêutica, método para preparar uma forma de dosagem unitária farmacêutica bicamadas e método para preparar uma forma de dosagem unitária farmacêutica tri-camadas
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3322747A (en) * 1965-04-01 1967-05-30 Merck & Co Inc Thionocarbonate nucleosides
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
JPS5943550B2 (ja) * 1975-08-29 1984-10-23 田辺製薬株式会社 不飽和ヌクレオシドの製法
DE3515870A1 (de) * 1985-05-03 1986-11-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 5-fluortoluol-2,4-disulfochlorid
US4710492A (en) * 1986-06-23 1987-12-01 Yale University 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses
NL8700089A (nl) * 1987-01-15 1988-08-01 Stichting Rega V Z W Therapeutische toepassing van dideoxythymidine en dideoxythymidineen.
DE3806633A1 (de) * 1987-09-01 1989-03-09 Bayer Ag Antivirales mittel
JP2648329B2 (ja) * 1987-09-18 1997-08-27 エフ・ホフマン−ラ ロシュ アーゲー エイズの予防または治療用医薬組成物
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
JPH0227782A (ja) * 1988-07-15 1990-01-30 Hikari Gijutsu Kenkyu Kaihatsu Kk 半導体発光素子
JPH0438727A (ja) * 1990-06-04 1992-02-07 Sharp Corp 光学式ピックアップ装置の対物レンズ塵埃付着防止機構

Also Published As

Publication number Publication date
PT86346A (en) 1988-01-01
IE60866B1 (en) 1994-08-24
KR960000433B1 (ko) 1996-01-06
NL960024I2 (nl) 1997-06-02
JPH07116041B2 (ja) 1995-12-13
EP0273277B1 (en) 1992-06-24
FI875544A (fi) 1988-06-18
DK557087D0 (da) 1987-10-23
FI875544A0 (fi) 1987-12-16
EP0273277A2 (en) 1988-07-06
EP0273277A3 (en) 1989-09-13
IL84790A0 (en) 1988-05-31
PT86346B (pt) 1990-11-07
US4978655A (en) 1990-12-18
IL84790A (en) 1993-03-15
NZ222935A (en) 1990-09-26
DE3780016T2 (de) 1992-12-24
ES2038650T3 (es) 1993-08-01
IE873245L (en) 1988-06-17
GR3005691T3 (ko) 1993-06-07
AU8090087A (en) 1988-06-23
PH26380A (en) 1992-06-01
EG19157A (en) 1994-09-29
LU88822I2 (fr) 1997-01-06
ATE77554T1 (de) 1992-07-15
DK174627B1 (da) 2003-07-28
DK557087A (da) 1988-06-18
DE3780016D1 (de) 1992-07-30
CA1293447C (en) 1991-12-24
JPS63215632A (ja) 1988-09-08
ZA877171B (en) 1988-03-24
HK55896A (en) 1996-04-03
NL960024I1 (nl) 1996-12-02
AU593405B2 (en) 1990-02-08

Similar Documents

Publication Publication Date Title
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
ES2076279T3 (es) Medicamentos que, como principio activo, contienen acidos carboxilicos con contenido en azufre, asi como su empleo para combatir retrovirus.
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
JPS6425A (en) Medicinal composition for treating hiv infection containing dsrna and reverse transcriptase inhibitor
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
Kemper et al. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex
KR910700045A (ko) Hiv 감염 관련 질병의 치료
KR880007073A (ko) 의 약 품
DE69322251T2 (de) Medizinische zusammensetzung
KR970025615A (ko) 암 전이 억제제
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR880007074A (ko) 의약품
Cornbleet SULFOXONE (DIASONE®) SODIUM FOR DERMATITIS HERPETIFORMIS
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
KR890004705A (ko) 항바이러스성 제제
KR970705563A (ko) 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent)
KR920703112A (ko) 의약품 조성물
KR890009401A (ko) 바이러스를 억제시키는 방법
FR2694693B1 (fr) Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
BR0007627A (pt) Mutações de hiv-1 selecionadas por beta-2', 3' -didehidro-2', 3' -didesóxi-5-fluorocitidina
KR900701301A (ko) 후천성 면역 결핍증과 연관된 골수억제증의 치료방법
KR910004190A (ko) 온단세트론의 신규 의학 용도
KR910007528A (ko) 벤조디아제핀 및 페닐피릴케톤 유도체의 용도
US3764679A (en) Iodinin as an anti-hypertensive agent

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010104

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee